Guardant Health account plan
advanced cancer detection technology
At a glance
Guardant Health is a precision oncology company selling blood and tissue cancer tests, with $982.0 million revenue in 2025 and 2,506 employees.
Guardant Health sells blood and tissue tests, real-world data and AI analytics across cancer care: screening (Shield), recurrence monitoring (Guardant Reveal) and therapy selection (Guardant360), plus tests, companion diagnostic development and data services for biopharmaceutical companies. Its customers are oncologists, primary care physicians, cancer centers and health systems, reimbursed by Medicare and commercial payers, and biopharma companies; 96% of 2025 revenue came from the United States. FY2025 revenue was $982.0 million, up 33%, with a net loss of $416.3 million. It had 2,506 employees at December 31, 2025, and labs in Redwood City, Long Island City, San Diego and Palo Alto. It is run by Co-CEOs Helmy Eltoukhy and AmirAli Talasaz.
Business units
Oncology
$683.6 million FY2025 revenue (about 70%, computed)Guardant360 CDx, Guardant360 Liquid, Guardant360 Tissue and Guardant Reveal for clinicians, cancer centers and partner labs. Revenue grew 26% in 2025 on about 276,000 tests; Q3 2026 revenue was $231.3 million (+25%) on 117,000 tests, with Reveal volume more than doubling.
Biopharma & data
$210.1 million FY2025 revenue (about 21%, computed)GuardantINFINITY and GuardantOMNI tests, companion diagnostic development, the GuardantINFORM real-world data platform and GuardantConnect trial matching for drug developers. Q3 2026 revenue was $59.0 million (+8%), and cumulative CDx approvals reached 31 globally.
Screening
$79.7 million FY2025 revenue (about 8%, computed)Shield, the first FDA-approved blood test for primary colorectal cancer screening, sold to primary care with direct-to-consumer campaigns, plus Shield MCD and lung screening in development. Q3 2026 revenue was $67.6 million (+180%) on about 83,000 tests, and 2026 guidance is $233-$238 million.
Licensing and other
$8.6 million FY2025 revenue (about 1%, computed)Technology licensing revenue, down from $13.5 million in 2024, which included nonrecurring milestone revenue; $3.1 million in Q3 2026.
Strategic priorities
- Scale Shield screening
- Grow Shield through the field organization, the Quest collaboration and DTC campaigns; coverage is expected to reach about 100 million people, more than 80% of the eligible U.S. population, entering 2027.
- Cut Shield cost per test
- Shield cost per test fell from $410 in Q2 to $330 in Q3 2026, with a new automated Palo Alto lab going live in 2027 and a target of $200 by the end of 2028.
- Repeat testing in therapy selection
- Guardant360 Liquid CDx (FDA-approved in 2026) and the camizestrant CDx approval push toward testing at each therapy decision; ADLT status is expected in the first half of 2027.
- Reveal Ultra and MRD
- Reveal Ultra launched to biopharma partners with clinical launch before year-end 2026; management calls it the biggest opportunity in the portfolio.
- Free cash flow breakeven
- The business excluding Screening generates positive free cash flow in 2026, and company-wide free cash flow breakeven is targeted by the end of 2027.
- Data and AI platform
- The Smart Platform and InfinityAI engine draw on more than 1.5 million patient tests and more than 900,000 epigenetic profiles, with smart apps and a conversational AI decision-support pilot.
Latest results
In Q3 2026 revenue rose 36% to $361.0 million from $265.2 million, with Oncology at $231.3 million (+25%), Screening at $67.6 million (+180%) and Biopharma & Data at $59.0 million (+8%). Non-GAAP gross margin was 67% versus 66%, while the net loss widened to $124.4 million from $92.7 million as legal expenses and sales and marketing rose. Adjusted EBITDA loss narrowed to $37.3 million and free cash flow was $(37.2) million. 2026 revenue guidance was raised to $1.36-$1.37 billion (+38% to 40%), with a free cash flow burn of $205-$220 million. Cash, cash equivalents and restricted cash were $1.1 billion at September 30, 2026.
Investments and deals
- MetaSight Diagnostics acquisition
- Acquired in December 2025 for $59.0 million upfront plus up to $90.0 million contingent on commercial performance and regulatory approvals.
- Shield lab capacity and automation
- A higher-throughput, lower-COGS Shield workflow approved and deployed in 2026, and a new automated Palo Alto lab going live in 2027.
- Commercial build-out
- Sales and marketing rose 36% to $494.7 million in 2025 for the Shield launch, with a field organization of over 400 professionals.
- Financing
- In 2025, $402.5 million of convertible notes and $257.1 million of equity raised, and $600.0 million of 1.25% 2031 notes exchanged for 2027 notes.
- International partner labs
- In-country labs with VHIO, Royal Marsden, Policlinico Gemelli and Adicon, and Shield MCD launched in multiple Asian markets.
Challenges and risks
- Continued losses
- Net loss of $416.3 million in 2025 and an accumulated deficit of $3.4 billion at September 30, 2026.
- Reimbursement timing and variability
- CMS cannot process Guardant360 liquid CDx claims until January 2027, shifting $10 million to $15 million of payments; payer rate setting and coding changes add variability.
- Litigation
- The TwinStrand verdict was upheld with a 6% ongoing royalty and $110.2 million held as surety collateral; legal expenses rose $22.6 million in Q3 2026.
- Competition
- Competitors include Foundation Medicine (Roche), Caris, Tempus AI, NeoGenomics, Exact Sciences, Natera, GRAIL and Freenome.
- Cybersecurity incident
- Unauthorized access to its electronic ordering portal, where an unauthorized party is believed to have accessed certain patient records; the investigation continues.
What leadership says
“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma”
“Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests”
“We remain confident in achieving company-wide free cash flow breakeven by the end of 2027.”
“Every commercial product runs on the platform”
Where a supplier can help
- Lab automation and sequencing efficiency
- Tied to the Shield cost per test priority: automation, robotics and workflow tools for the new Palo Alto lab on the path to $200 per test.
- Security and patient data protection
- Tied to the cybersecurity incident: identity, portal security and monitoring solutions for physician ordering and patient records.
- Revenue cycle and payer contracting
- Tied to the reimbursement challenge: billing, claims and contracting tools as commercial coverage and ADLT status expand.
- Direct-to-consumer marketing
- Tied to the Shield scale-up priority: media, patient engagement and primary care outreach as DTC spending increases into 2027.
- AI and data infrastructure
- Tied to the data and AI platform priority: compute, data management and clinical AI tooling for the InfinityAI engine and physician decision support.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Guardant Health?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Guardant Health Form 10-K for fiscal year 2025
- Guardant Health is a precision oncology company selling blood and tissue tests across screening (Shield), recurrence monitoring (Guardant Reveal) and therapy selection (Guardant360 CDx, Guardant360 Liquid, Guardant360 Tissue), plus tests, data and services to biopharmaceutical companies; all run on its Smart Platform and InfinityAI learning engine.
- FY2025 revenue was $982.0 million, up 33% from $739.0 million; net loss narrowed to $416.3 million from $436.4 million; accumulated deficit $3.0 billion.
- Revenue mix: Oncology $683.6 million (+26%, ~276,000 tests), Biopharma & data $210.1 million (+18%), Screening $79.7 million (~87,000 Shield tests, first full year), Licensing and other $8.6 million.
- Shield is the first FDA-approved blood test for primary colorectal cancer screening and meets Medicare coverage requirements; it was added to NCCN guidelines (June 2025), got CMS ADLT status (March 2025), VA (March 2025) and TRICARE (January 2026) coverage; Shield MCD has FDA Breakthrough Device designation.
- Sales and marketing expense jumped 36% to $494.7 million to support the Shield launch; R&D was $364.2 million (+5%); one operating and reportable segment, run by Co-CEOs Helmy Eltoukhy and AmirAli Talasaz.
- 96% of 2025 revenue came from the United States ($923.3 million); international revenue was $58.7 million, sold through partner labs (VHIO, Royal Marsden, Policlinico Gemelli, Adicon) and distributors.
- Balance sheet: about $1.3 billion of cash, restricted cash and marketable debt securities; $600.0 million of 1.25% 2031 convertible notes issued in exchange for $659.3 million of 2027 notes; $402.5 million of new convertible notes and $257.1 million equity raised in 2025.
- December 2025 acquisition of MetaSight Diagnostics for $59.0 million upfront plus up to $90.0 million contingent consideration.
- Key risks: continued losses, payer reimbursement variability, competition (Foundation Medicine, Tempus AI, Natera, Exact Sciences, GRAIL and others), Illumina supply dependence, and litigation including the $83.4 million TwinStrand jury verdict and the $292.5 million jury award Guardant won against Natera.
- Guardant Health Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 revenue $361.0 million, up 36% from $265.2 million; nine-month revenue $997.6 million, up 42%.
- Oncology $231.3 million (+25%) on about 117,000 tests (from about 74,000); Screening $67.6 million (+180%) on about 83,000 Shield tests (from about 24,000); Biopharma and data $59.0 million (+8%).
- Q3 net loss $124.4 million (Q3 2025: $92.7 million); G&A up 71% to $90.9 million, mainly a $22.6 million rise in legal expenses; sales and marketing up 39% to $177.2 million.
- Guardant360 Liquid CDx won FDA approval in Q2 2026 and met Medicare coverage requirements; an ADLT application followed.
- UnitedHealth Group covers Shield from August 1, 2026, the first major commercial insurer to cover average-risk adults 45+; Shield is in NCCN and American Cancer Society guidelines and Shield MCD has launched in several Asian markets.
- Cash, cash equivalents and restricted cash of $1.1 billion; accumulated deficit $3.4 billion; the 2031 and 2033 convertible notes became convertible for Q4 2026 after the share price trigger.
- TwinStrand: in June 2026 the court upheld the verdict and granted a 6% ongoing royalty; Guardant will appeal.
- New risk disclosure: unauthorized access to its electronic ordering portal, in which an unauthorized party is believed to have accessed certain patient records.
- Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
- Q3 2026 revenue $361.0 million (+36%): Oncology $231.3 million (+25%, 117,000 tests, +58%), Screening $67.6 million (+180%, 83,000 Shield tests, +246%), Biopharma & Data $59.0 million (+8%).
- Non-GAAP gross margin 67% (Q3 2025: 66%); adjusted EBITDA loss $37.3 million; free cash flow $(37.2) million; cash, cash equivalents and restricted cash $1.1 billion.
- 2026 revenue guidance raised to $1.36-$1.37 billion (+38% to 40%), from $1.34-$1.36 billion.
- Screening 2026 guidance $233-$238 million on 285,000-290,000 Shield tests; Oncology revenue growth about 30% with volume growth over 50%; Biopharma & Data low double-digit growth.
- Non-GAAP operating expenses now $1.105-$1.125 billion; free cash flow burn $205-$220 million.
- Milestones: FDA approval and CE mark of Guardant360 CDx as companion diagnostic for AstraZeneca's camizestrant (first liquid biopsy CDx for longitudinal testing in breast cancer); Guardant360 Tissue PMA submitted; Guardant Reveal Ultra launched with biopharma partners; Shield commercial coverage above 80% of eligible lives, including UnitedHealth Group, Carelon and EviCore.
- Guardant Health Q3 2026 earnings call transcript
- Co-CEO Helmy Eltoukhy says the Smart Platform underpins "four of the largest opportunities in precision medicine": therapy selection, MRD, cancer screening and, over time, multi-disease screening.
- Q3 revenue $361 million (+36%); Oncology $231 million, test volume +58% to 117,000; Guardant360 liquid volume grew nearly 30%, Reveal volume more than doubled.
- FDA approval of Guardant360 CDx for AstraZeneca's camizestrant: the first FDA-approved protocol to switch therapy when a resistance marker (ESR1) emerges; about 37,000 U.S. women with HR+/HER2- advanced breast cancer, testing every 3 months.
- Data asset: more than 1.5 million patient tests and more than 900,000 epigenetic profiles; fourth wave of 11 smart apps on Guardant360 liquid; pilot of a conversational AI decision-support agent for physicians.
- Reveal Ultra launched to biopharma, clinical launch before year-end; Eltoukhy calls it "probably the biggest opportunity we have in our portfolio".
- Shield: revenue $68 million (+180%), 83,000 tests (+246%), ASP above $800; about 100 million people (over 80% of the eligible U.S. population) expected to be covered entering 2027; cost per test cut from $410 in Q2 to $330 in Q3, target $200 by end of 2028.
- CFO Michael Bell raised 2026 revenue guidance to $1.36-$1.37 billion; free cash flow burn $205-$220 million because CMS cannot process Guardant360 liquid CDx claims until January 2027; company-wide free cash flow breakeven targeted by end of 2027.
- Guardant Health Q2 2026 earnings call transcript
- Q2 2026 revenue $335 million (+44%): Oncology $219 million (+38%, volume +63% to about 104,000 tests), Biopharma & Data a record $61 million (+9%), Screening $53 million on about 66,000 Shield tests.
- Eltoukhy sizes the four opportunities (therapy selection, recurrence monitoring, cancer screening, multi-disease screening) at "nearly $400 billion in potential markets".
- FDA approved Guardant360 Liquid CDx in May, "100x more content" than the legacy CDx; phased rollout, widespread availability after ADLT designation expected in the first half of 2027.
- 28 CDx approvals, 4 in the first half of 2026; new CDx with Boehringer Ingelheim (HERNEXEOS) and Arvinas/Pfizer (VEPPANU); Nuvalent collaboration.
- Shield: ACS guideline inclusion (May 2026), UnitedHealth coverage from August 1, about 70 million lives (roughly 60% of the market) covered; field organization over 400; addressable U.S. screening market $50 billion across about 120 million average-risk people.
- FDA approved a higher-throughput, lower-COGS Shield workflow; Shield cost per test about $410, target $200 in 2028; Guardant360 Liquid move to NovaSeq X cut cost per test by about $200.
- Guidance raised to $1.34-$1.36 billion revenue; free cash flow burn $195-$205 million due to Shield lab capex; breakeven still targeted by end of 2027.
Questions about Guardant Health
What does Guardant Health do?
Guardant Health sells blood and tissue tests for cancer screening (Shield), recurrence monitoring (Reveal) and therapy selection (Guardant360), plus tests, data and companion diagnostic services for biopharma companies.
What is Guardant Health's revenue?
FY2025 revenue was $982.0 million, up 33%. Q3 2026 revenue was $361.0 million, and 2026 guidance is $1.36-$1.37 billion.
How many employees does Guardant Health have?
Guardant had 2,506 employees at December 31, 2025, about 2,278 in the U.S.
What is Guardant Health's strategy?
Guardant aims to lead in therapy selection, MRD and early cancer screening on its Smart Platform, scaling Shield, cutting test costs and reaching company-wide free cash flow breakeven by the end of 2027.
Who leads Guardant Health?
Co-founders Helmy Eltoukhy and AmirAli Talasaz are Co-CEOs; Michael Bell is CFO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)